| Mode Of Action | Pralidoxime (2-PAM) reactivates cholinesterases (and other enzymes such as neurotoxic target esterase and pseudocholinesterase) inactivated by organophosphates. It is also thought to bind directly to organophosphates |
|---|---|
| Drug Indication | Organophosphate poisoning (normally used with atropine) |
| Precautions | Reduced dose in renal disorders |
| Side Effects | Nausea, weakness, diplopia, blurred vision, mild neuromuscular blockade |
| Dosage | Adult: IV, 2g initially then 500 mg/hr IV infusion. Child:IV, 50 mg/kg initially then 20mg/kg/hr IV infusion |
| Drug Category | DRUGS AFFECTING NUTRITION AND METABOLISM |
| Drug Sub-Category | Antidotes and gastrointestinal decontaminants |